LANCE LABNO, PT, DPT, LMT · A WRITTEN EXCHANGE WITH AMAN MAHENDRA
From pain relief to moving again.
A temporary nerve implant is an intriguing starting point. The starting point is now total knee replacement: helping people recover safe movement, confidence, and daily life in the first two weeks.
Evidence reviewed November 16, 2026 · Independent Movement Solutions discussion brief · Not a Northwestern study protocol or endorsement
A NOTE FROM LANCE
Four answers for the first two weeks after TKA.
A response to Aman’s follow-up, keeping the focus on daily movement.
Subject: Re: Early recovery after total knee replacement
Hi Aman,
Thank you for clarifying the shift from nerve cooling to a temporary electrical stimulator with an external wearable. Total knee replacement gives us a useful starting point. My perspective comes from physical therapy, massage therapy, and working with pain and movement at Movement Solutions.
• When does pain get in the way? I would focus on the first few steps after sitting or lying down, getting out of a chair or off the toilet, bending and straightening the knee, and completing short walks and prescribed exercises. The transition home is especially worth studying: what can the person manage between visits? I would ask about sleep and symptom changes as medication or a nerve block wears off. Pain, swelling, quadriceps inhibition, fatigue, and fear of movement can overlap, so I would not assume pain alone explains a stalled recovery.
• What would I do, and where are the gaps? My approach would be to reassess what is limiting the task, check for concerning changes, and coordinate with the surgical team when needed. I would adjust the movement, support, walking aid, and amount of practice; use appropriate swelling and comfort measures; and build back toward meaningful activity. Medication changes belong with the prescribing team. The gap is often carrying relief into daily function: less pain does not necessarily restore muscle control, sleep, confidence, or help at home. Treatment side effects and the work of managing another device also matter.
• What would convince me it was helping? A repeatable everyday change: getting to the bathroom or rising from the same chair with less help, completing a useful short walk more comfortably, or participating more consistently in prescribed exercise. I would record pain during the task alongside assistance, walking distance or time, steadiness, and the later symptom response. I would also want preserved strength and sensation, without more falls or medication side effects. The improvement should matter to the patient and persist beyond one good session.
• Who else should you ask? An acute-care PT who sees patients before discharge, a home-health PT working during the first two weeks, a joint-replacement nurse navigator, and a regional-anesthesia or acute-pain clinician. An occupational therapist can add insight about toileting, dressing, and the home setup. Patients and caregivers can describe the hours between appointments. I do not have a specific introduction arranged, but those perspectives would complement mine.
One additional question is what the device comes to mean to the person: reassurance and greater freedom to move, or another sensation to monitor and worry about. That is worth exploring without overlooking physical irritation or complications.
I’ve updated the research page at https://pain-to-movement.labnolabs.com/ with the knee-replacement focus and study ideas. Please send the technical brief for the current electrical device, including its nerve target and development stage. I’m happy to continue with questions by email.
Best, Lance Labno, PT, DPT, LMT Movement Solutions
Background checked against the Movement Solutions biography. [31] Clinical suggestions are a proposed approach, not a report of audited practice outcomes. Supporting evidence and limits appear below.
THE CLINICAL QUESTION / A USEFUL WINDOW
Relief is an opening. Movement is the test.
The first two weeks are a useful observation window, not a promise that everyone should reach the same milestone on the same day.
What current care already offers
The July 2026 APTA guideline replaces the 2020 version. It supports movement retraining, progressive rehabilitation, early quadriceps NMES, and individually appropriate supervised care. Pain modalities may add modest benefit within a broader plan. Coordination is recommended by consensus, with limited direct evidence. [35]
Surface NMES activates muscle. TENS, implanted PNS, nerve cooling, and intraoperative monitoring have different purposes and cannot share an efficacy claim.
Where another treatment must add value
PROSPECT recommends a multimodal pathway including suitable nonopioid medicines, adductor canal block and periarticular infiltration, with opioids reserved for rescue. Patient-specific contraindications matter. [36]
Study question: Does adding the new device improve function beyond well-delivered existing care, without an unacceptable burden or safety tradeoff?
Proposed observation plan, individualized by the treating team. These are study design suggestions, not recovery deadlines.
Window
Everyday task
What to separate
Before discharge
Bed/chair transfer and a short permitted walk
Task pain versus dizziness, sensation, quadriceps control, and help required
First days at home
Bathroom trip, getting up after rest, prescribed exercises
Relief during use versus wearable burden, access to help, medication timing, and later symptoms
Through day 14
Repeat the same task and a personally meaningful activity
A single good session versus repeatable benefit and safe progression
After treatment ends
Repeat function and device/tissue review
Benefit that persists versus loss of benefit, new symptoms, or reliance on reassurance
A practical success example: the person completes the same bathroom route with the prescribed aid and less human assistance, reports less task pain, and remains steady. Record route, time, help, symptoms, and later response. This is an illustrative goal—not a validated responder threshold.
Why pain and movement can diverge
A 2026 retrospective TKA cohort found quadriceps inhibition in 44.5% of 229 patients at day 30 and 19.2% at day 60. Its classification was not specifically validated for TKA, and associations do not prove causation. The useful implication is to measure muscle function separately from pain; these later observations do not estimate first-week implant benefit. [45]
Make a responder claim earn its place
Choose one primary task outcome and its assessment time before the trial. Record baseline task ability, quadriceps control, medication use, expectations, sleep, and support needs. Compare randomized groups with the same rehabilitation access. Improvement in one group alone can reflect normal healing.
Test only a few prespecified treatment interactions. A factor that predicts slower recovery is not necessarily a factor that predicts greater device benefit. Use a separate cohort to validate a responder model; do not exclude people because of attachment style or a “nocebo-prone” label.
New or worsening neurological changes, wound concerns, or unexpected deterioration require clinical reassessment. Proposed psychological explanations must not replace that assessment.
COMPANY RESEARCH / REVIEWED NOVEMBER 16, 2026
Where MPOWERHealth fits.
Its clearest verified role is supporting surgical teams. A potential role in an implant study would need to be defined and tested.
Relationship status: the reviewed primary sources do not establish an MPOWERHealth partnership with Rogers’s lab, involvement in Aman’s project, or manufacture of this implant. No independent acute-TKA efficacy evidence for the new implant was identified.
A July 2022 company release announced a Texas retrospective bundled-payment program with BCBSTX, spanning surgery and postoperative care; it also named 360CareNav.
A relevant episode-of-care model. Current operation, contracts, rehabilitation access, and comparative patient outcomes remain unverified.
Who is responsible?
The current leadership page lists Scott LaRoque, founder/CEO; Chris Matthews, president; Allie Robért, EVP/chief clinical operations officer; and Amy Malphrus, MD, chief medical officer. [40]
Malphrus’s official biography describes neurology and clinical-neurophysiology training at Baylor and extensive IONM work. That is relevant expertise, not proof of a TKA pain-device program. [41]
Who pays?
The patient FAQ describes participation with government plans and out-of-network status with most commercial insurers, with applicable surprise-billing protections. This is company-reported policy, not verification of a patient’s coverage. [42]
For a proposed implant pathway, request the full episode cost: placement, wearable, staff training, follow-up, troubleshooting, rehabilitation, complications, and patient time. Public pricing for this investigational pathway was not identified.
How strong are the outcomes claims?
Ament et al. (2023) combined a large provider dataset with economic modeling for spine-surgery IONM. MPOWERHealth supplied data and research funding. The modeled benefit depends on clinical and payment assumptions; this is not an independent randomized trial, a TKA rehabilitation study, or evidence for Aman’s device. [44]
Evidence applicability map. Color indicates source type, not a numerical quality score or formal GRADE rating.
Question
Available support
What remains open
Does MPOWERHealth provide OR services?
Current company descriptions [37–42]
Procedure-specific staffing and local availability
Does its IONM offer economic value?
Company-funded spine model [44]
Independent validation and transfer to other procedures
Has it operated a TKA care model?
Historical 2022 announcement [43]
Current results, access, savings, and complication rates
Will Aman’s implant improve early TKA function?
Not established for this exact device
Technical identification, safety, and a comparative human trial
How it could work with the new concept
The following is a proposed division of responsibilities, not an existing collaboration. A company like MPOWERHealth could contribute implementation knowledge if its role, capabilities, and incentives fit.
Define placement workflow, training, neurological assessment, escalation, and follow-up ownership.
USE & EVALUATE
Patient + rehab team
Observe movement, home burden, experience, and safety. Feed results back into design.
Five questions before treating it as a partner
Which role would MPOWERHealth actually fill: surgical support, recruitment, safety monitoring, home follow-up, or payment coordination?
What current TKA results can it share with patient counts, baseline complexity, comparators, therapy access, and missing-data rates?
Who is clinically responsible after discharge, and what happens if the wearable fails or neurological symptoms appear?
Who pays, who bears financial risk, and how are adequate rehabilitation and patient choice protected?
Would it support independent analysis, prespecified outcomes, publication rights, and follow-up after the device stops functioning?
An unanswered question is a due-diligence gap, not evidence of poor care. Company marketing, historical announcements, research results, and proposed relationships are labeled separately.
FOUR SIDES / KEEP THE VALUE, SEE THE TRADEOFF
Blessing. Cost. Curse. Insight.
A blessing is the useful effect in the right setting. A cost is paid even when it works. A curse is what can happen when that cost goes unseen or the approach no longer fits. An insight keeps the value and adds one practical adjustment.
These are proposed design interpretations, not measured incidence rates or allegations about a company. Device benefits remain conditional on evidence.
Temporary pain relief
BlessingA window to practice a meaningful task.
CostPlacement, training, monitoring, and patient attention still take resources.
CurseA lower pain score is mistaken for restored strength or permission to overload.
Reveal the insight +
Keep the relief; pair it with a repeatable safe task and a later symptom check.
Bioresorption
BlessingMay avoid a planned removal procedure, if the whole design permits it.
CostFunctioning lifetime and material breakdown must still be verified.
Curse“Dissolving” is heard as “no follow-up needed,” and a problem is missed.
Reveal the insight +
Keep the temporary design; specify what dissolves, when it stops working, and the rescue plan.
Attention to the body
BlessingA person can notice useful changes and adapt movement.
CostAttention takes effort; recovery also needs rest and ordinary life.
CurseConstant checking turns every sensation into an alarm or activity becomes avoidance.
Reveal the insight +
Keep awareness; use short, purposeful check-ins followed by a chosen activity.
Human support
BlessingHelp can make practice more manageable and less isolating.
CostSupport requires time and must fit the person’s preferences.
CurseReassurance becomes intrusive or the person feels unable to move without approval.
Reveal the insight +
Keep connection; offer choice and gradually return decisions to the person.
Surgical monitoring
BlessingSignals may alert clinicians to a developing neurological problem.
CostStaff, equipment, interpretation, and procedure-specific indication are required.
CurseMonitoring is mistaken for a guarantee of safety or proof of pain-treatment efficacy.
Reveal the insight +
Keep the signal; define the response pathway and measure the outcome it is meant to protect.
Episode-based payment
BlessingThe whole recovery can become a shared responsibility.
CostCoordination, data collection, and financial risk require resources.
CurseSpending becomes the only success measure, hiding inadequate rehab or unequal access.
Reveal the insight +
Keep accountability; report patient function, harms, access, and spending together.
Clinical and technical context: [2], [24], [30], [35], [37], [43]. The adjustments are hypotheses to examine, not validated implant protocols.
VISUAL ATLAS / SEE THE RELATIONSHIPS
What changes the signal. What changes the experience.
Pain often draws attention and prompts protection. It is not a reliable meter of damage, and it does not always carry a decipherable message. Biological, psychological, and social processes can contribute together. [12]
2D / RELATIONSHIP MAP
Follow a connection; then ask what could be observed.
Conceptual synthesis. Lines mean “consider together,” not measured causal strength. This map does not diagnose a person’s pain.
3D / THREE CONNECTED LAYERS
Rotate to see the layers. Flatten to read them together.
01 · BODYTissue, nerves & deviceWhat is happening physically?
02 · EXPERIENCELearning & expectationWhat does this sensation predict?
03 · RELATIONSHIPSChoice, trust & supportWhat helps this person participate?
A conceptual 3D model, not brain anatomy, a biological hierarchy, or measured distances. The layers coexist: physical mechanisms, learned meaning, and relationship context. Color and depth imply no evidence ranking.
Evidence heatmap: where does the support come from?
Read across each row before carrying a finding into this proposed implant study. Colors mark evidence type; words show its reach. This is a scoped evidence map, not a formal GRADE certainty assessment.
Human trialsAnimal testsContext / mixed findingsFrameworkGap
Evidence reviewed November 16, 2026. Select a row’s title to open its source entry.
These are four study conditions, not four kinds of patients. The axes indicate whether an investigational device and an added support/practice program are included. All groups retain appropriate usual care.
Added support + practice ↑
B / SUPPORT
Usual care + structured support
Test explanation, preferred support, and permitted movement practice.
D / COMBINED
Device + structured support
Test the novel relationship: does support help translate analgesia into participation?
A / COMPARATOR
Usual care
Establish the recovery course with ethical, credible control procedures.
C / DEVICE
Usual care + device
Estimate device benefit with the same basic communication and rehabilitation access.
Investigational device added →
Proposed 2×2 factorial design, contingent on device safety, approvals, feasibility, and a power calculation. A sham may be appropriate only if ethically acceptable. Interaction tests require more power than a small feasibility pilot.
Novel hypothesis: the combination could change task participation even when resting pain changes little. Test whether the combined effect differs from the sum of separate effects; do not assume synergy.
ASSOCIATED PAIN / LEARNING WITHOUT BLAME
Could the treatment itself become a cue?
A device has physical effects and an experience attached to it. Its appearance, sensations, or treatment setting might come to predict relief, uncertainty, or pain. That is a plausible research question—not an established problem with Rogers’s implant.
Physical pathway
Surgical healing, inflammation, nerve effects, stimulation delivery, or a device complication can contribute to pain.
Investigate symptoms and device function clinically.
Learning and context pathway
Prior experiences, instructions, attention, and expectations can change pain and willingness to move—even with the same experimental stimulus. [24][25]
Measure meaning and expectations alongside physical findings.
Both pathways can be present. Pain is real in either case. Fluctuation, normal imaging, or improvement with reassurance does not establish a nocebo diagnosis. New or worsening pain around an implant requires assessment for surgical, tissue, nerve, and device-related causes.
Movement paired with pain acquired threat value in an experimental setting.
Does not make all guarding learned, unnecessary, or safe to override.
Turn the concern into an ethical feasibility study
Before exposure: ask what the person expects to feel, what benefit or harm they anticipate, and which treatment experiences shape those expectations. Record baseline symptoms and function.
During use: align symptom timing with device parameters, activity, sleep, medication, and clinical findings. Worsening pain may prompt device use, so a correlation can run in either direction.
Investigate reported problems: assess physical and device causes before attributing symptoms to expectations. Record tolerability, skin/tissue issues, motor and sensory effects, and adverse events.
Test a support component: compare equally accurate explanations, transparent familiarization, or patient-chosen support. Preserve consent, rescue care, and the ability to stop; no deceptive settings changes in routine care.
Measure participation: record movement pain, permitted task performance, assistance, confidence, and delayed symptoms. Analyze expectation and attachment measures as exploratory moderators—not exclusion labels.
These are proposed research steps requiring clinical investigators, ethics review where applicable, and an appropriate analysis plan. A small pilot can establish feasibility; it cannot validate a responder algorithm.
INTERPERSONAL NEUROBIOLOGY / AN ORGANIZING LENS
Body, mind, and connection.
Dan Siegel’s interpersonal neurobiology (IPNB) brings embodied experience, mental processes, and relationships into one interdisciplinary framework. “Integration” refers to linking differentiated elements. It is a way to organize questions—not a proven implant treatment. [30]
Notice
Can the person describe what they feel and distinguish location, intensity, timing, and the task involved?
Observe: symptom descriptions and task-specific responses.
Choose
Does the person understand the plan and have meaningful control over permitted options?
Observe: understanding, perceived agency, and preferences.
Connect
Does support feel responsive and welcome? Who, if anyone, does the person want involved?
Observe: trust, preferred support, and participation.
These are proposed operational questions inspired by IPNB. Neither IPNB nor right-brain attachment theory establishes which neural process is causing an individual’s pain. Attachment involves distributed systems; “right brain” is not a readiness score. [13][23]
Diverts cerebrospinal fluid for selected hydrocephalus cases.
Can the person recognize problems and follow the monitoring plan?
Proposed temporary nerve implant
Intended nerve modulation or block; exact mechanism still needs confirmation.
Does relief translate into safe activity, and what experience does the person have while using it?
These examples illustrate different purposes, not equivalent evidence or indications. Body awareness and social support do not replace a clinically necessary device.
Lance’s clinical emphasis: helping people understand their bodies, explore appropriate movement, and connect with others can sit alongside effective technology. The research should test how those pieces work together.
01 / THE CONVERSATION
What is their study about?
Aman’s team is exploring an early-recovery use case for an investigational device. His follow-up identifies total knee replacement and a temporary, bioresorbable peripheral nerve stimulator operated with an external wearable.
Now clarified by Aman
The project began with nerve cooling. It has shifted toward electrical stimulation from Professor John Rogers’s team, still in development. The team is gathering clinician perspectives; a registered human trial or approved treatment has not been established in the supplied material.
Still needed from the team
The exact technical brief, nerve target, intended sensory and motor effects, implant and wearable design, functioning and resorption timelines, safety data, and human/regulatory stage. Course instructor, team roster, sponsor, and formal protocol remain unconfirmed.
Working question: Can the device create a useful window for safe movement—and what else does a person need to use that window?
How the idea could help—and what could be missing
Potential value
Missing piece to test
Movement Solutions contribution
Localized, adjustable analgesia
Does benefit occur during walking, transfers, or exercise—not only at rest?
Choose repeatable, surgery-appropriate tasks.
Less reliance on rescue medication
Comparable pain control, side effects, sleep, and actual medication use
Connect analgesia timing with therapy participation.
A temporary interface
Working lifetime, breakdown products, retained components, and failure/removal plan
Test whether the whole setup is practical at home.
More opportunity to practice movement
Strength, sensation, balance, surgical restrictions, and delayed symptom response
Document both what a person can do and the support needed.
A stronger recovery experience
Whether explanation, choice, and preferred support add benefit
Help design a reproducible communication approach.
These are proposed benefits and design questions. Existing clinical PNS trials support investigating analgesia; they do not validate every Rogers prototype. [6][7]
02 / IDENTIFY BEFORE GENERALIZING
“Temporary nerve implant” can mean different things.
Aman has clarified the direction: a bioresorbable electrical stimulator with an external wearable. The published devices below are background examples, not identification of that current device. The cooling cuff is the confirmed historical starting point. [34]
Animal evidence
Electrical nerve block · 2022
Lee and colleagues developed a bioresorbable cuff delivering kilohertz-frequency alternating current to block conduction in rat peripheral nerves. Reported fast, reversible block; experimental power/control used external connections.
Must establish: human benefit, onset responses, selective sensory effects, and safe motor function. This is not interchangeable with low-frequency clinical PNS. [1]
Animal evidence
Cooling cuff · 2022
Reeder and colleagues used a soft, bioresorbable microfluidic interface to cool a nerve and reversibly reduce conduction. It requires fluid delivery; it is not an electrical stimulation implant.
Must establish: temperature safety, selective effects, home hardware burden, and human recovery outcomes. [2]
Animal evidence
Heating interface · 2026 volume
Park and colleagues report a largely bioresorbable cuff with a heater and temperature sensor. Rat sciatic conduction was suppressed and recovered on cooling; wireless power was demonstrated. First online December 2025.
Must establish: human thermal safety and what remains after degradation. Gold elements are biocompatible, not bioresorbable. [3]
Open two related platforms that address different goals +
2025 wireless dual stimulator: Ahn and colleagues studied peripheral nerve regeneration in animal models. Regeneration is a different endpoint from early postoperative analgesia. [4]
2026 programmable polyphasic system: Kim and colleagues developed wireless power and light-controlled waveforms. The reported platform includes cardiac and diaphragm applications; its existence does not establish pain relief after orthopedic surgery. [5]
Keep three distinctions visible: stimulation ≠ conduction block; temporary ≠ fully dissolving; animal nerve response ≠ better human recovery. Aman identifies the general electrical-stimulation concept; its exact technical identity and regulatory status remain unconfirmed.
03 / PEOPLE & RESPONSIBILITIES
A research network, with roles to confirm.
Only Aman and John Rogers are named in the email. Publication authors below are relevant to the technology; their involvement in Aman’s course team has not been confirmed.
Person / connection
Verified relevance
Useful question
Aman Mahendra Student contact
Education and project purpose are self-described in the email. The linked professional profile lists Northwestern education, 2023–2027. [17]
Which course, instructor, teammates, and specific device are involved?
John A. Rogers Northwestern professor
Director of the Querrey Simpson Institute for Bioelectronics; expertise in soft, bio-integrated and transient electronics. Coauthor of the candidate devices. [18]
Which mechanism and development milestone are relevant now?
Matthew R. MacEwan WashU collaborator
Research spans peripheral nerve interfaces, regeneration, and transient electronics. Coauthor on electronic and thermal pain-block work. [1][3][19]
How are nerve health, motor effects, and repeat-use safety evaluated?
Geumbee Lee / Emily Ray 2022 publication authors
Lead authors on the electronic pain-block paper; Lee is also a corresponding author of the thermal interface paper. [1][3]
What does the prototype actually block, for how long, and with what external equipment?
Jeonghwan Park / Hak-Young Ahn Recent device authors
Park leads the thermal-interface paper; Ahn leads the wireless dual-stimulator paper and coauthors the thermal work. [3][4]
Which performance measures transfer to a postsurgical use case?
Colin K. Franz Shirley Ryan AbilityLab
Physician-scientist and Electrodiagnostic Laboratory director studying neural injury, repair, and transient bioelectronic implants. Corresponding author on the 2025 regeneration study. [4][21]
Could a rehabilitation collaborator help distinguish nerve recovery, analgesia, and functional performance?
Brian Ilfeld / Johnathan Goree Independent clinical comparators
Lead authors of clinical PNS trials discussed below. Not established as members of Aman’s or Rogers’s project. [6][7]
What can an acute or persistent-pain trial teach about controls and endpoints?
No faculty member is assumed to teach Aman’s entrepreneurship course. Credentials support expertise, not the effectiveness of a particular device.
04 / WHAT HAS ACTUALLY BEEN TESTED?
Promising human evidence. Different hardware.
Randomized pilot · 66 patients
Acute orthopedic recovery: Ilfeld et al., 2021
Fourteen days of percutaneous PNS or sham followed ambulatory orthopedic surgery. In the first week, median opioid use was 5 versus 48 mg oral morphine equivalents; mean daily average pain was 1.1 versus 3.1 out of 10. Both groups also received a single-injection nerve block. [6]
Active PNS1.1 / 10
Sham3.1 / 10
Bars use a 0–10 pain scale. Group means, not an individual prediction. Pilot size, mixed surgeries, and a different device limit transfer to Rogers’s prototypes.
Randomized trial · persistent pain
After knee replacement: Goree et al., 2024
During weeks 5–8, at least 50% pain reduction occurred in 12/20 PNS participants (60%) versus 5/21 sham participants (24%). Six-minute walking distance also improved more with PNS at end of treatment. This studied persistent pain after knee replacement—not the first postoperative week. [7]
Small study; devices remained for eight weeks. DoD and SPR Therapeutics supported the study. Review disclosures and the full protocol before choosing it as a model.
Randomized trial · 317 patients
Why a credible control matters: Rakel et al., 2014
TENS during knee-replacement rehabilitation reduced some movement pain compared with standard care, but did not significantly outperform placebo TENS. Anxiety and catastrophizing were associated with some response differences. TENS is a surface treatment, not the proposed implant. [8]
Do not turn these exploratory associations into implant eligibility rules. Measure expectations and assess whether participants can guess their allocation.
Laboratory experiment · 39 women
Partner presence was not universally soothing
Krahé et al. found higher attachment avoidance was associated with greater laser-pain ratings when a partner was present rather than absent. This was a particular laboratory context, not surgical recovery. [9]
Laboratory experiment · 37 women
Support helped one sensory outcome; attachment did not moderate it
Jaltare et al. found a smaller area of experimentally induced secondary hyperalgesia during partner handholding. Attachment did not moderate that support effect. Different support, setting, and outcome can yield different findings. [10]
Observational clinical cohort
Attachment findings changed with clinical context
Pfeifer et al. compared unexplained musculoskeletal pain rehabilitation with hip-replacement care for osteoarthritis. Greater avoidance related to less pain improvement in the former and greater improvement in the latter. Different populations and treatments prevent a causal interpretation. [11]
What this means: investigate benefit with good controls. Do not combine these unlike studies into a single success percentage, or use attachment style to predict who will respond to this implant.
05 / ATTACHMENT, SAFETY & THE RIGHT BRAIN
The person receiving the signal matters too.
Pain is a real sensory and emotional experience shaped by biological, psychological, and social influences. Nociceptive activity alone does not tell us everything about a person’s pain. [12]
What “right-brain attachment” adds
Allan Schore’s regulation theory emphasizes early attachment, nonverbal communication, emotional regulation, and right-hemisphere contributions. It offers a conceptual reason to attend to voice, timing, facial expression, and interpersonal comfort. [13]
Boundary: this is a theoretical synthesis, not evidence that a right-brain intervention improves implant outcomes. Attachment and pain cannot be reduced to a single hemisphere. A small social-emotion imaging study found task-dependent associations in both right- and left-sided regions. [23] No reviewed study establishes a “right-brain readiness” test for this device.
Turn the theory into observable choices
Ask whether the person wants a preview, quiet practice, verbal coaching, a support person, or more control over pauses. Explain what sensations to expect and what should prompt stopping.
Record perceived safety, confidence for a specific task, participation, and adverse responses. Do not infer attachment from eye contact, muscle guarding, pain intensity, HRV, or a clinician’s impression.
This is a proposed care-and-study approach. It does not measure hemispheric activity or prove a neural mechanism.
Use dimensions and preferences, not fixed boxes.
Possible tendency
Question worth asking
Support to offer and test
Worry that help will disappear
“What would make the plan feel more predictable?”
Consistent explanations, a clear check-in plan, and a stop signal.
Preference for self-reliance or distance
“Would you prefer to try independently, with me nearby?”
Choice, privacy, and optional coaching; do not force closeness.
Mixed or changing preferences
“What is helpful right now?”
Recheck preferences across tasks and days.
These are conversation prompts, not diagnostic categories. With consent, the ECR-RS questionnaire could measure attachment anxiety and avoidance as separate dimensions. Specify whether the target is close relationships generally or one particular relationship. It is an exploratory research measure, not an implant-response screen. [22] In using it, select its version, permissions, and scoring with a qualified behavioral researcher. People with insecure attachment may still improve substantially.
Open the evidence gaps and mixed findings +
A 72-person chronic-pain rehabilitation study reported comparable treatment effectiveness across attachment groups. [14] A sequential-block clinician-training study found mixed results and did not establish a clear main pain benefit over usual care. It was not a randomized implant trial. [15]
A post-cesarean attachment pilot is indexed, but the accessible PubMed record has no abstract. Its results are not used here; obtain the complete paper before drawing conclusions. [16]
No reviewed evidence demonstrates that attachment-informed communication changes the electrical effect of this implant, identifies a validated responder subgroup, or prevents persistent postsurgical pain.
06 / A BETTER RESEARCH PATH
Test the device, the recovery, and the support.
Proposed research sequence—not an approved protocol. Start with the smallest study that resolves the current uncertainty.
A
Understand the problem
Interview patients, therapists, surgeons, and anesthesia staff about total knee replacement and the first two weeks. Ask for concrete episodes: getting to the bathroom, rising from a chair, or sleeping.
Output: a task map, current treatment pathway, and practical barriers. Interviews test need and feasibility, not efficacy. Use consent and de-identified examples.
B
Establish readiness
Review exact-device bench and animal data, functional lifetime, tissue response, motor/sensory effects, degradation, and recovery after shutoff.
Gate: qualified investigators determine readiness, regulatory requirements, and ethics approval before any investigational implantation. Do not translate animal settings into clinical doses.
C
Run a clinical feasibility pilot
Once authorized, focus on primary total knee replacement with standardized usual care. Test placement, home operation, retention, follow-up, safety, and whether the chosen task can be measured reliably.
Output: recruitment and missing-data estimates, adverse events, and outcome variability to plan a powered trial. A small pilot cannot reliably identify responder subgroups.
D
Test incremental benefit
Compare active device + usual care with credible sham + the same usual care, if an invasive sham is ethically justified. Keep rescue analgesia available. Use concealed allocation and blinded outcome assessment.
Alternative: an active-comparator trial when sham is unsuitable, acknowledging expectancy and masking limitations.
Two studies that do not require the implant
Prospective recovery cohort: follow one surgical population using the measurement schedule below. This can identify recovery predictors and practical barriers, but cannot tell whether a characteristic predicts extra benefit from the device.
Support feasibility experiment: with appropriate research review and consent, compare a structured, patient-chosen preview-and-coaching approach with an equally attentive standard explanation. Maintain usual analgesia and therapy in both groups. Measure acceptability, task completion, pain, and confidence; partner involvement or touch is optional. This can test the support component while device development continues.
Then ask whether communication adds benefit.
A later, adequately powered 2 × 2 factorial trial could separate device effects from an added structured support intervention. Everyone receives respectful care, rehabilitation, and rescue treatment.
Proposed four-arm design—no participant data
Usual supportive communication
Added structured support
Active device
Device benefit under usual care
Device + added choice, preview, and check-ins
Control device
Reference condition
Added support without active stimulation
Match contact time where possible. Define the support script and fidelity checks; do not train staff to diagnose attachment by behavior. Predefine the interaction analysis. A benefit from support would not, by itself, prove Schore’s proposed mechanism.
A practical measurement schedule
When
Measure
Why
Before surgery
Baseline pain and function; medications; sleep; expectations; anxiety; optional attachment dimensions and support preferences
Describe participants and prespecify a few plausible modifiers.
Early recovery / days 1–14
Pain during the same safe task; distance or time; assistance needed; strength/sensation; rescue medication; adverse events
Persistent pain, function, nerve symptoms, further treatment
Assess durability and delayed harms; do not assume prevention.
Illustrative measurement choices. Timing, loading, and permitted movement must match the operation and surgeon’s restrictions. No patient data is collected.
How to identify who benefits more
Predicting recovery is different from predicting treatment benefit. A person might improve with either treatment. A useful responder model must estimate whether the device adds benefit compared with control.
Prespecify a small set of candidate modifiers: procedure, baseline function, pain phenotype, medication exposure, and selected psychosocial measures.
Analyze treatment-by-characteristic interactions, preferably using continuous scores rather than arbitrary “high/low” categories.
Adjust for baseline status and surgical site; plan missing-data handling and multiple comparisons before recruitment. Have a statistician power the primary outcome and any confirmatory interactions.
Validate a proposed selection rule in new patients and sites before using it clinically. Report uncertainty, calibration, harms, and who was underrepresented.
Use attachment information to improve access and support—not to deny treatment or blame a person for pain.
A meaningful win: less task-related pain plus clinically meaningful function, without unacceptable weakness, sensory loss, falls, or device burden. Predefine the primary endpoint and procedure-specific meaningful difference with patients and clinicians; do not invent a universal success cutoff.
FIVE QUESTIONS / CONTINUE BY EMAIL
A useful direction for the next exchange.
Aman has supplied four questions, answered above. These five follow-up questions address the remaining design decisions for early knee-replacement recovery.
1. Which electrical device and development stage are we discussing?+
For the TKA use case, please send the current electrical-device description, nerve target, mechanism, wearable requirements, and development stage.
Recommendation: Keep TKA as the starting use case; identify the exact prototype and distinguish entrepreneurship discovery from a clinical protocol.
2. What should a person be able to do better?+
Choose a meaningful task and describe the expected improvement in pain, assistance, capacity, or participation.
Recommendation: Pair a pain measure with one safe, repeatable functional task and adverse-event monitoring.
3. Could the device become a cue for relief or threat?+
How will you capture expectations and the experience of using it while investigating physical causes of symptoms?
Recommendation: Include a small expectations-and-experience component; avoid labeling people as nocebo-prone.
4. What support belongs beside the device?+
Could explanation, choice, permitted movement practice, or patient-preferred human support improve the recovery experience?
Recommendation: Pilot a reproducible support component, then consider the four-condition design shown above.
5. How will you learn who benefits without prematurely excluding people?+
Which baseline measures and treatment interactions would you prespecify, and how would you validate any responder claim?
Recommendation: Use continuous measures, adequate sample size, uncertainty intervals, and independent validation. Attachment is exploratory, not an eligibility rule.
08 / FOLLOW THE EVIDENCE
Sources & reading notes
This is a targeted research synthesis, not a systematic review. Searches covered primary device papers, university profiles, human pain trials, attachment experiments, and clinical cohorts. Strongest direct evidence and conflicting findings are included. Sources were reviewed through accessible full text or abstracts; access limitations are marked.
Link supplied by Aman as historical project background. Direct retrieval was blocked; the published cooling paper [2] supplies the scientific evidence.